trending Market Intelligence /marketintelligence/en/news-insights/trending/Sf8wOvJ6pAv_an25h4ux_g2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Amunix licenses technology to Roche for $40M to develop non-cancer treatments

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Amunix licenses technology to Roche for $40M to develop non-cancer treatments

Amunix Operating Inc., a private biopharmaceutical company, entered an agreement to license its Xten technology platform to Roche Holding AG.

Roche intends to use the Xten technology platform, which directs infection-fighting cells in the immune system, to develop non-cancer treatments.

Switzerland-based Roche will pay the Mountain View, Calif.-based Amunix $40 million upfront and up to $1.5 billion in development and sales-based milestones, plus royalties on sales of commercialized products.

"This agreement further validates our foundational Xten technology and its continued potential for biopharmaceutical partners seeking to develop drugs with augmented half-life and low associated immunogenicity," said Amunix CEO Angie You.